Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

The all-important Employment Situation report for July — nonfarm payrolls and unemployment — is out this morning, and results ...

Regeneron reports strong Q2 2025 growth with Dupixent sales up 21% and EYLEA HD hitting record highs. Explore key earnings insights and pipeline updates.

REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO ...

The all-important Employment Situation report for July — nonfarm payrolls and unemployment — is out this morning, and results ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Sanofi missed analyst projections of $1.32 with Q2 earnings per share (EPS) of $1.25. Revenue was €9.89 billion, which was ...

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decreased 25% in ...